
























368Outcomes of Hematologic Malignancies after Unrelated
Donor Hematopoietic Cell Transplantation According
to Place of Residence
Fausto R. Loberiza, Jr.,1 Stephanie J. Lee,2 John P. Klein,3 Anna Hassebroek,4 Jason G. Dehn,5
Haydar A. Frangoul,6 Theresa Hahn,7 Gregory Hale,8 Hillard M. Lazarus,9
Charles F. LeMaistre,10 Richard T. Maziarz,11 J. Douglas Rizzo,3 Navneet S. Majhail4,12Studies suggest that patients who live in rural areas may have worse clinical outcomes compared with patients
living in urban areas. We studied whether place of residence (rural versus urban) is associated with clinical
outcomes of patients with leukemia or myelodysplastic syndrome (MDS) who received an unrelated donor
hematopoietic cell transplantation (HCT). Patients’ residential ZIP code at the time of transplant was used to
determine rural or urban designation based on the Rural Urban Commuting Codes. The study included 6140
patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from
121 U.S. HCT centers: 1179 (19%) came from rural areas, whereas 4961 (81%) came from urban areas. Rural
and urban patients were similar in patient-, disease-, and transplant-related characteristics aside from house-
hold income and distance traveled to the HCT center. After adjusting for income and other significant pa-
tient, disease, and transplant-related variables, the risk of overall mortality between patients residing in
rural and urban areas were not statistically significant (relative risk 1.01, 95% confidence intervals 0.93-
1.10, P 5 .74). Similar outcomes were noted for treatment-related mortality (TRM), disease-free survival
(DFS), and relapse. Patient’s income, derived from the U.S. Census and based on their residential ZIP
code, was independently associated with outcomes. In summary, our study showed no differences in the clin-
ical outcomes of patients from rural or urban areas after unrelated donor HCT.
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Hematopoietic cell transplantation (HCT) is
a complex treatment procedure for various malignant
and nonmalignant hematologic disorders [1-5]. Pa-
tients who undergo allogeneic HCT often experience
posttransplant complications, which may lead to pro-
longed hospitalizations, readmissions, or even death.
Because of the high-risk nature and intensive resource
dependence of allogeneic HCT, not all facilities are
able to offer this treatment modality. Patients who
may benefit from allogeneic HCT are often referred
to larger treatment centers. In theUnited States, trans-
plant centers are usually located in metropolitan or ur-
ban areas and attract a wide range of patients,
including many who come from small towns and rural
areas. Transplanted patients often stay in the hospital
or close to the transplant center for an extended time
during the peritransplant period. Patients from rural
areas or small towns usually return to their communi-
ties and referring health care providers for follow-up,
usually after a period of observation and medical
management when appropriate. These health care
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have the expertise in detecting complications that usu-
ally occur post-HCT.
Studies have shown that rural residents must travel
from 2 to 10 times the distance of their urban counter-
parts to access advanced care, including HCT [6-8].
Physician shortages also force many of these patients
to travel great distances for specific care related to their
posttransplant follow-up [9,10]. Additionally, rural pa-
tients often have lower income than their urban coun-
terparts, all of which may contribute to poor follow-up
care. Rao et al. [8] noted that patients from rural areas
who received autologous HCT from a single Midwest
center had a higher risk of death than urban patients
who underwent the same procedure. They noted
a 5% lower survival rate at 1 and 5 years post-HCT
among patients from rural areas compared to patients
from urban areas. However, they failed to detect a sig-
nificant difference in the risk of death according to pri-
mary area of residence in the HLA-identical sibling
HCT cohort, although this may have been because
of lack of statistical power. It is not known if the char-
acteristics and clinical outcomes of patients with acute
or chronic leukemia who underwent unrelated HCT
differ according to place of residence. We hypothe-
sized that patients who live in rural areas may not be
able to receive optimal posttransplant care when
needed, which may predispose them to have inferior
clinical outcomes.METHODS
Data Source
The Center for International Blood and Marrow
Transplant Research (CIBMTR) is a research affilia-
tion of the International Bone Marrow Transplant
Registry (IBMTR), Autologous Blood and Marrow
Transplant Registry (ABMTR) and the National Mar-
row Donor Program (NMDP), which comprises a vol-
untary working group of more than 450 transplant
centers worldwide that contribute detailed data on
consecutive allogeneic and autologous HCT to a Sta-
tistical Center at the Medical College of Wisconsin in
Milwaukee and the NMDP Coordinating Center in
Minneapolis. Participating centers are required to re-
port all transplants consecutively; compliance is mon-
itored by on-site audits. Patients are followed
longitudinally, with yearly follow-up. Computerized
checks for errors, physicians’ review of submitted
data, and on–site audits of participating centers ensure
data quality. Observational studies conducted by the
CIBMTR are done so with a waiver of informed con-
sent and in compliance with HIPAA regulations as de-
termined by the institutional review board and the
Privacy Officer of the Medical College of Wisconsin.Subjects
Patients who received an unrelated donor alloge-
neic HCT with a myeloablative (MA) preparative reg-
imen using either a bone marrow (BM) or peripheral
blood stem cell (PBSC) source for acute myelogenous
leukemia (AML), acute lymphoblastic leukemia
(ALL), chronic myelogenous leukemia (CML), or
myelodysplastic syndrome (MDS), between 1995 and
2004, were included in the study. The study was fur-
ther limited to transplant centers located within the
continental United States and to patients with avail-
able residential postal zip codes; 67 patients with miss-
ing zip codes were excluded.
All surviving recipients included in this analysis
were retrospectively contacted and provided informed
consent for participation in the NMDP research pro-
gram. Informed consent was waived by the NMDP in-
stitutional review board for all deceased recipients.
Approximately 10% of surviving patients would not
provide consent for use of research data. To adjust
for the potential bias introduced by exclusion of non-
consenting surviving patients, a corrective action
plan modeling process randomly excluded appropri-
ately the same percentage of deceased patients
(n 5 534) using a biased coin randomization with ex-
clusion probabilities based on characteristics associ-
ated with not providing consent for use of the data in
survivors [11]. The final study cohort consisted of
6140 patients representing 121 U.S. transplant centers
(Table 1).Study Variables
Place of residence was defined according to the
Rural Urban Commuting Area (RUCA) code assigned
to the zip code of the patient’s primary residence at the
time of transplant [12]. The RUCA classification was
dichotomized into urban or rural designations. The
RUCA defines patients’ location as either urban
($50,000 residents), large rural (10,000 to 49,000 res-
idents), small rural (2500 to 9999 residents), or isolated
(\2499 residents) based on the Census Bureau’s defi-
nitions of Urbanized Areas and Urban Clusters, which
in turn, rely on complex criteria including population
density and population work commuting patterns.
The RUCA classification system is based on the size
of cities and towns and their functional relationships
as measured by work commuting. For this study, rural
areas included those from large rural, small rural, and
isolated. Information about patient race was center-
reported and categorized according to the U.S. Office
of Management and Budget classification as White,
African-American,Hispanic, or Asian/Pacific-Islander.
Patient income was estimated by the mean household
income at the zip code level based on the 2004 U.S.
Census. The distance between the patient’s residence
and the transplanting center were approximated using
Table 1. Characteristics of U.S. Patients Who Received Unrelated Myeloablative Transplants for AML, ALL, CML, and MDS from
1995 to 2004
Variable Rural N (%) Urban N (%) P-value
Patient related
Number of patients 1179 4961
Number of centers 97 121
Age, median (range), years 34 (<1-67) 33 (<1-70) .61
Age at transplant, years .96
<1-9 131 (11) 583 (12)
10-19 169 (14) 700 (14)
20-29 195 (17) 828 (17)
30-39 238 (20) 1024 (21)
40-49 284 (24) 1143 (23)
$ 50 162 (14) 683 (14)
Male sex 659 (56) 2844 (57) .37
Race/ethnicity <.001
White 1103 (94) 4091 (82)
African-American 42 (4) 324 (7)
Asian/Pacific Islander 7 (1) 131 (3)
Hispanic 27 (2) 415 (8)
Karnofsky status .04
<90 323 (27) 1221 (25)
$90 796 (68) 3415 (69)
Missing 60 (5) 325 (7)




0-1 comorbidities 1085 (92) 4545 (92)
$2 comorbidities 94 (8) 416 (8)
Disease related
Disease .17
AML 419 (36) 1632 (33)
ALL 287 (24) 1289 (26)
CML 331 (28) 1490 (30)
MDS 142 (12) 550 (11)
Disease status at transplant .71
Early 436 (37) 1920 (39)
Intermediate 379 (32) 1530 (31)
Advanced 327 (28) 1364 (27)
Unknown 37 (3) 147 (3)
Transplant related
Time from diagnosis to transplant, median (range), months 11 (2-309) 11 (1-309) .72
Missing 2
Graft type .37
Bone Marrow 976 (83) 4051 (82)
Peripheral blood 203 (17) 910 (18)
Infused cell dose
Bone marrow >2  108 591 (61) 2484 (62) .61
Bone Marrow # 2 x 108 374 (39) 1534 (38)
Missing 11 33
Peripheral blood >5  108 126 (65) 571 (68) .25
Peripheral blood #5  108 68 (35) 272 (32)
Missing 9 67
HLA match status .15
Well-matched 493 (42) 2147 (43)
Partially matched 461 (39) 1793 (36)
Mismatched 225 (19) 1021 (21)
Sex match (donor/recipient) .43
Male/male 437 (37) 1877 (38)
Male/female 298 (25) 1142 (23)
Female/Mmle 222 (19) 967 (19)
Female/female 222 (19) 975 (20)
CMV match (donor/recipient .11
Negative/negative 412 (35) 1641 (33)
Negative/positive 356 (30) 1393 (28)
Positive/negative 161 (14) 809 (16)
Positive/positive 231 (20) 1032 (21)
Unknown 19 (2) 86 (2)
Conditioning regimen .36
Bu + Cy ± other 217 (18) 955 (19)
Cy + TBI ± other 867 (74) 3535 (71)
TBI ± other 42 (4) 181 (4)
Other 53 (5) 290 (6)
(Continued )
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Table 1. (Continued )
Variable Rural N (%) Urban N (%) P-value
Year of transplant .34
1995-1999 610 (52) 2490 (50)
2000-2004 569 (48) 2471 (50)
Distance to center, median (range), miles 124 (8-4207) 43 (<1-5194) <.001
Distance to center <.001
<17 3 (<1) 1346 (27)
17-55 143 (12) 1358 (27)
56-150 547 (46) 999 (20)
>150 484 (41) 1248 (25)
Missing 2 (<1) 10 (<1)
Region* <.001
New England 49 ( 4) 332 ( 7)
Mid-Atlantic 95 ( 8) 651 (13)
South Atlantic 132 (11) 580 (12)
East North Central 201 (17) 778 (16)
East South Central 136 (12) 196 ( 4)
West North Central 238 (20) 371 ( 7)
West South Central 146 (12) 625 (13)
Mountain 26 (2) 147 (3)
Pacific 156 (13) 1281 (26)
Donor search time, median (range), months
Diagnosis to preliminary search 3 (<1-300) 3 (<1-303) .90
Preliminary search to formal search <1 (<1-77) <1 (<1-116) .06
Formal search to transplant 3 (<1-71) 3 (<1-125) <.001
Median follow-up of survivors, months 63 (5-136) 61 (3-138)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myleogenous leukemia; MDS, myelodysplastic syndromes;
TBI, total body irradiation; Bu, busulfan; cy, cyclophosphamide; CMV, cytomegalovirus.
*States comprising geographic region of transplant center:
2New England 5 ME, NH, VT, MA, RI, CT.
2Mid-Atlantic 5 NY, NJ, PA.
2South Atlantic 5 DE, MD, DC, VA, WV, NC, SC, GA, FL.
2East North Central 5 OH, IN, IL, MI, WI.
2East South Central 5 KY, TN, AL, MS.
2West North Central 5 MN, IA, MO, ND, SD, NE, KS.
2West South Central 5 AR, LA, OK, TX.
2Mountain 5 MT, ID, WY, CO, NM, AZ, UT, NV.
2Pacific 5WA, OR, CA, AK, HI.
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gitude of the zip code [13]. The package ‘‘ZIP Code
deluxe’’ [14] was used to obtain income and location
data from the zip code.
Disease status at transplant was classified as early,
intermediate, or advanced. Early disease included
AML and ALL in first complete remission (CR1),
CML in first chronic phase (CP1), and MDS with re-
fractory anemia or refractory anemia with ringed side-
roblasts (RA, RARS). AML and ALL in second or
greater remission or CML in accelerated phase or sec-
ond or greater CP was categorized as intermediate dis-
ease. Patients with advanced disease had AML and
ALL in relapse or primary induction failure, CML in
blast phase, or MDS with refractory anemia with ex-
cess blasts or excess blasts in transformation (RAEB,
RAEB-t).
The NMDP classification of HLAmatching status
based on best available resolution of typing was used to
categorize HLAmatching status as well-matched, par-
tially matched, or mismatched [15]. Briefly, well-
matched patients had no identified mismatches at
HLA-A, -B, -C, and -DRB1 with low/intermediate
or high resolution data available at HLA-A, -B, andhigh-resolution -DRB1. Partially matched patients
had a single locus mismatch at any of the 4 loci
and/or missing HLA-C data. Mismatched patients
had 2 or more allele or antigen mismatches.Outcomes and Study Definitions
The primary outcome of interest in this study is
overall survival (OS), defined as death from any cause.
Additional outcomes evaluated included disease-free
survival (DFS), relapse, and treatment-related mortal-
ity (TRM). DFS was defined as survival in complete
remission after HCT. Relapse was defined as disease
recurrence at any site, with TRM as a competing
risk. TRM was defined as death in CR with relapse
as a competing risk.Statistical Analysis
Patient-, disease-, and HCT- related characteris-
tics were compared according to rural or urban dis-
tinction using the chi-square statistic for categoric
variables or Kruskal-Wallis test for continuous vari-
ables. Probabilities of OS and DFS were calculated us-
ing the Kaplan-Meier method. Probabilities of TRM
372 Biol Blood Marrow Transplant 16:368-375, 2010F. R. Loberizam et al.and relapse were calculated using the cumulative-inci-
dence function method. OS, DFS, TRM, and relapse
were estimated from the time of transplant.
Cox proportional hazards regression analyses were
used to examine the association between place of resi-
dence and study outcomes. The followingmodels were
built to examine the association between place of resi-
dence and outcomes: (1) unadjusted model with place
of residence or income alone as covariate; (2) place of
residence with other statistically significant patient-,
disease-, and transplant-related factors; and (3) model
number 2 with income included. All variables were first
examined to assure that they complied with the pro-
portional hazards assumption. The final multivariate
models were built using a forward stepwise model
selection approach. Factors significant at an alpha of
5% were kept in the final model; all P-values are 2
sided. The multivariate models for DFS and TRM
were stratified on the Karnofsky Score. Separate
models limited to centers that had at least 5 rural and
5 urban patients were also performed to investigate
whether volume effects could account for the findings.
These models produced similar results and are not
presented here. In addition, the effect of transplant
center was tested in each model; the results were again
similar to the analysis presented here and are therefore
not included. Analyses were performed using SAS soft-
ware, version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Table 1 shows the comparison of patient-,
disease-, and transplant-related characteristics ac-
cording to patients’ primary area of residence. Of
the 6140 patients included in the study, 1179 (19%)Table 2. Adjusted and Unadjusted Models Evaluating the Associatio
Treatment-Related Mortality
A. Overall S
Main Variable Unadjusted Model Adjusted for income*
Urban 1.00 1.00
Rural 1.09 (1.01-1.18) 1.00 (0.92-1.09)
P 5 .02 P 5 .99
B. Treatment-relat
Main Variable Unadjusted Model Adjusted for Income*
Urban 1.00 1.00
Rural 1.08 (0.98-1.18) 0.98 (0.88-1.08)
P 5 .10 P 5 .66
*Income entered as quartiles: <$34,700, 34,700-43,600, 46,600-56,300, >$56,
†Adjusted for graft type and cell dose, HLA-match, patient age, disease type,
recipient match, race/ethnicity, and year of transplant.
‡Model stratified for Karnofsky performance score.came from rural areas, whereas 4961 (81%) came
from urban areas. Of the 121 centers included in
this study, 97 (80%) performed HCT on patients
who came from rural areas. The median proportion
of patients coming from rural areas was 20% per cen-
ter (range: 1%-74%). Patients from rural areas were
more likely than patients from urban areas to be
White (94% versus 82%), have lower median income
($34,000 versus $48,000), and travel longer distances
to the transplant center (124 miles versus 43 miles).
Rural patients were also more likely to be trans-
planted in the areas commonly referred to as the
U.S. Midwest region (East North and South Central,
West North Central areas).Outcome Analysis
Table 2A shows the analysis evaluating the associ-
ation between place of residence and risk of death post-
transplant. In the unadjusted model, rural patients
were 9% more likely to die than urban patients (rela-
tive risk [RR] 1.09, 95% confidence interval [CI]
1.01-1.18, P5 .02). This association remained statisti-
cally significant after adjusting for important patient,
disease, and transplant-related variables (RR 1.08,
95% CI 1.00-1.17, P 5 .05). However, when the
models were adjusted for income in addition to other
prognostic variables, the association between place of
residence and risk of death was no longer significant
(RR 1.01, 95% CI 0.93-1.10, P 5 0.75). Tables 2B,
3A, and 3B show no statistically significant association
between place of residence and risk of TRM, treat-
ment-failure, and relapse in both unadjusted and ad-
justed models. Figure 1 shows the Kaplan-Meier plot
of the probability of survival, and Figure 2 shows the
cumulative incidence of TRM according to place of
residence.n between Place of Residence and (A) Overall Survival and (B)
urvival
Adjusted for Patient,
Disease and Tx Char†
Adjusted for Patient, Disease and
Tx Char and Income*†
1.00 1.00
1.08 (1.00-1.17) 1.01 (0.93-1.10)
P 5 .05 P 5 .75
ed mortality‡
Adjusted for Patient,
Disease and Tx Char†
Adjusted for Patient, Disease
and Tx Char and Income*†
1.00 1.00
1.08 (0.98-1.18) 1.00 (0.91-1.11)
P 5 .11 P 5 .94
300.
disease stage, number of comorbidities, cytomegalovirus (CMV) donor-
Table 3. Adjusted andUnadjustedModels Evaluating theAssociation between Place of Residence and (A)Disease-free survival and
(B) Relapse
A. Disease-free survival‡
Main Variable Unadjusted Model Adjusted for Income*
Adjusted for Patient,
Disease, and Tx Char†
Adjusted for Patient,
Disease, Tx Char, and
Income*†
Urban 1.00 1.00 1.00 1.00
Rural 1.06 (0.98-1.14) 0.97 (0.89-1.05) 1.05 (0.97-1.14) 0.99 (0.91-1.07)
P 5 .15 P 5 .48 P 5 .20 P 5 .76
B. Relapse
Main Variable Unadjusted Model Adjusted for Income*
Adjusted for Patient,
Disease, and Tx Char†
Adjusted for Patient,
Disease, Tx Char, and
Income*†
Urban 1.00 1.00 1.00 1.00
Rural 1.04 (0.90-1.18) 0.98 (0.85-1.13) 1.02 (0.89-1.16) 0.97 (0.83-1.12)
P 5 .61 P 5 .78 P 5 .83 P 5 .66
*Income entered as quartiles: <$34,700, 34,700-43,600, 46,600-56,300, >$56,300.
†Adjusted for graft type and cell dose, HLA-match, patient age, disease type, disease stage, number of comorbidities, cytomegalovirus (CMV) donor-
recipient match, race/ethnicity, and year of transplant.
‡Model stratified for Karnofsky performance score.
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Table 4 shows the primary causes of death re-
ported by HCT centers according to area of residence.
The most common cause of death regardless of area of
residence was disease recurrence (25%), followed by
infection (20%) and multiorgan failure (18%). There
is a slightly higher proportion of patients from rural
areas who died from infection (all etiologies), 22% ver-
sus 19%, P 5 .05. Other causes of death appear to be
similar in rates between patients from rural and urban
areas.DISCUSSION
The possibility of health care disparities according
to place of residence raises concerns about equitable
access. In general, health care access has 2 fundamental
elements: (1) ability of individuals to get care when
needed in a reasonable time frame and (2) once underFigure 1. Probability of OS according to place of residence.care, the ability of the systems to move patients across
providers and through the stages of care (coordination
of care) to assure good outcomes [16,17]. Although
these concepts are familiar, there are very few data re-
garding disparities in access to care in the setting of
HCT. Our study was able to examine some aspects
of the second element of access: do the characteristics
and clinical outcomes of patients who were able to re-
ceive unrelated HCT differ according to place of res-
idence? Our study is the largest evaluation of
whether rural or urban residence is associated with
outcomes of unrelated donor HCT.We found that ex-
cept for household income and distance traveled to
transplant centers, rural patients who undergo unre-
lated HCT are generally comparable to their urban
counterparts in terms of clinical characteristics. Rural
patients are also similar to urban patients with respect
to donor search times (preliminary to formal search),
time from diagnosis to transplant, and all parametersFigure 2. Probability of treatment-related mortality according to place
of residence.
Table 4. Causes of Death According to Place of Residence
Cause of death Rural Urban P-value
Graft rejection or failure 16 (2) 67 (2) .88
Infection 183 (22) 636 (19) .05
Interstitial pneumonia 108 (13) 402 (12) .45
Acute GVHD 65 (8) 323 (10) .10
Chronic GVHD 45 (5) 176 (5) .86
Recurrence or persistence
of primary disease
210 (25) 824 (25) .72
Organ failure 137 (17) 598 (18) .34
Secondary malignancy 8 (1) 32 (1) .99
Hemorrhage 31 (4) 163 (5) .16
Other 21 (3) 91 (3) .75
GVHD indicates graft-versus-host disease.
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level of HLA matching, etc.), all of which may have
some prognostic significance. Given these overwhelm-
ing similarities, it is reassuring that there are no differ-
ences in OS and TRM between rural and urban
patients when adjustments are made for income, dis-
ease, and transplant factors.
A previous single center study [8] also noted simi-
larities in the clinical characteristics of patients who
undergo HCT according to place of residence. This
study also documented survival differences between
rural and urban autologous patients but not recipients
of HLA-identical sibling HCT. One reason why out-
comes may differ in autologous transplantation but
not allogeneic transplantation according to place of
residence is that most patients who receive unrelated
HCT and HLA-identical sibling HCT remain under
the care of the transplanting physician for an extended
period of time. This is not the case with autologous
HCT recipients who return more quickly to their
referring physicians. It is also possible that rural pa-
tients who are able to access unrelated donor HCT
have resources similar to those of urban patients but
are different than rural patients who were not able to
access HCT.
Although rural/urban designation was not associ-
ated with outcome, income was associated with sur-
vival and TRM. Other studies in different cancer
populations have implicated the prognostic role of in-
come rather consistently [18-21]. Our study is not able
to explore further the interaction between the 2 factors
as both rural-urban distinction and estimated income
were derived from the same zip code. Ideally, actual in-
come and rural/urban designation should be collected
directly from patients rather than relying on zip code
to better explore these factors. Given the impact of in-
come in all of the clinical outcomes studied, future
studies may have to consider this socioeconomic fac-
tor. Other factors linked with supportive care, includ-
ing availability of caregivers, may have somemediating
impact on clinical outcomes. Our study was also not
able to separate patients whose HCT were paid for
by Medicaid as this information is not available.Although our study represents the largest cohort to
evaluate rural-urban disparity in the setting of unre-
lated HCT, it is limited by the retrospective observa-
tional study design. Our study was not able to
address the question of whether rural patients who
are likely to benefit from HCT are able to receive
this treatment modality similarly to patients who re-
side in urban areas. This is probably the most impor-
tant question regarding access that current available
data is not able to answer. Our study is also not able
to explore possible reasons why zip code-derived in-
come was associated with outcome. However, it is im-
portant to note that income may be used as a means to
identify vulnerable populations who may be at risk for
developing inferior outcomes. Additional studies are
needed to look more closely at the process of delivery
of care, including follow-up care, according to income
levels and area of residence to begin to understand po-
tential causes for inferior outcomes.ACKNOWLEDGMENTS
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